Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]

Group 1 - The company held its 23rd meeting of the 5th Board of Directors on November 11, 2025, where all 9 directors were present and agreed to waive the notice period requirement [2][4] - The Board decided not to exercise the early redemption rights for the "Saili Convertible Bonds" due to the stock price meeting the redemption trigger conditions, which is 130% of the conversion price [3][19] - The company will not redeem the bonds for the next three months, and if the redemption conditions are triggered again after February 12, 2026, the Board will reconvene to decide on the matter [20][9] Group 2 - The company plans to provide a guarantee of up to RMB 80 million for its subsidiaries to support their daily operations and business development [25][31] - The guarantee will be valid for twelve months following the Board's approval and will not exceed 10% of the company's latest audited net assets [26][33] - The Board unanimously approved the guarantee proposal, indicating that the subsidiaries are under the company's control and have a good credit status, making the guarantee risk manageable [32][31]

Core Points - The company announced that its stock has met the conditions for the early redemption of its convertible bonds, known as "塞力转债," due to the closing price being at least 130% of the conversion price for 15 out of the last 30 trading days [2] - The board of directors decided not to exercise the early redemption rights for the "塞力转债" at this time [2] - The company will not exercise the early redemption rights for the next three months, and if the redemption conditions are triggered again after February 12, 2026, the board will reconvene to decide on the matter [2]

Core Points - The company announced that it will hold the 23rd meeting of the fifth board of directors on November 11, 2025, to review a proposal for providing guarantee limits for its subsidiaries [1] - The total guarantee amount for the subsidiaries, including Shanghai Selis Medical Technology Co., Ltd., Selis Biological Technology Co., Ltd., and Huali Zhiwei (Shanghai) Diagnostic Technology Co., Ltd., is expected to be no more than RMB 80 million [1] - The guarantees will be provided in various forms, including but not limited to guarantees, pledges, and mortgages, with the actual guarantee amount and duration to be determined by the final signed agreement [1] - The expected validity period for the guarantees is within twelve months after the board's approval [1] - There are no counter-guarantees required for the subsidiaries being guaranteed, as they are all controlled subsidiaries of the company [1]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-097 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 54,331万元，期限6年。本次发行的可转换公司债券的票面利率为：第一年0.50%， 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。上述 资金已于2020年8月27日全部到位，并经中审众环会计师事务所（特殊普通合伙） 于2020年8月27日出具的众环验字（2020）010054号验资报告审验，扣除承销保 荐费用及与本次可转换公司债券发行直接相关的其他发行费用（含增值税）后的 募集资金净额为人民币53,269.80万元。 （二）可转换公司债券上市情况 塞力斯医疗科技集团股份有限公司 关于不提前赎回"塞力转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和 ...

信达证券股份有限公司 关于塞力斯医疗科技集团股份有限公司 不提前赎回"塞力转债"的核查意见 信达证券股份有限公司（以下简称"信达证券""保荐机构"）作为塞力斯医 疗科技集团股份有限公司（以下简称"塞力医疗""公司"）公开发行可转换公司 债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》及 《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》等相关 规定，经审慎核查，就塞力医疗不行使"塞力转债"的提前赎回权利，发表如下 核查意见： 一、可转换公司债券发行上市概况 （一）可转换公司债券发行情况 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306 号文同意，公司发行总额为 人民币 54,331.00 万元的可转换公司债券于 2020 年 9 月 15 日起在上海证券交易 所挂牌交易，债券简称"塞力转债"，债券代码"113601"。 经中国证券监督管理委员会（证监许可【2020】1033 号）核准，公司于 2020 年 8 月 21 日公开发行了 543.31 万张可转换公司债券， ...

| | | 塞力斯医疗科技集团股份有限公司 关于为控股子公司提供担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 被担保人名称 | | 塞力斯（上海）医疗科技有限公司 | | --- | --- | --- | --- | --- | | | | 本次担保金额 | 5,000 万元 | | | 担 保 象一 | 对 | 实际为其提供的担保余额 | 0 万元 | | | | | 是否在前期预计额度内 | □是 □否 | ☑不适用：新增预计额度 | | | | 本次担保是否有反担保 | □是 ☑否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 | | 武汉塞力斯生物技术有限公司 | | | | 本次担保金额 | 2,000 万元 | | | 象二 | | 实际为其提供的担保余额 | 0 万元 | | | | | 是否在前期预计额度内 | □是 □否 | ☑不适用：新增预计额度 | | | | 本次担保是否有反担保 | □是 ☑否 | □ ...

第五届董事会第二十三次会议决议公告 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-096 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 （一）审议通过《关于不提前赎回"塞力转债"的议案》 自 2025 年 10 月 22 日至 2025 年 11 月 11 日收盘，公司股票已有十五个交易 日的收盘价不低于"塞力转债"当期转股价格的 130%（即 15.60 元/股），已触 发"塞力转债"的有条件赎回条款。 全体董事均亲自出席本次董事会； 无董事对本次董事会议案投反对/弃权票； 本次董事会全部议案已获通过。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日在公司 A 栋 C 会议室以现场和通讯相结合的方式临时召开第五届董事会第 二十三次会议。经全体董事一致同意，本次会议豁免通知时限要求。 ...

Group 1 - The core point of the article is that Sely Medical (SH 603716) held a temporary board meeting on November 11, 2025, to discuss the proposal for providing guarantee limits for its subsidiary [1] - For the fiscal year 2024, Sely Medical's revenue composition is 97.09% from commercial activities and 2.91% from industrial activities [1] - As of the report date, Sely Medical has a market capitalization of 4.9 billion yuan [1] Group 2 - Prior to the arrest of Peking University Pharmaceutical's chairman Xu Xiren, police had investigated the group's factory premises, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by Xu, with significant amounts of funds unaccounted for [1]

Core Insights - The pharmaceutical commercial sector experienced a decline of 0.52% on November 6, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - The top-performing stock was HeFu China (603122), which closed at 14.34, up 9.97% with a trading volume of 1.2541 million shares and a transaction value of 1.757 billion [1] - Other notable gainers included Yinghe Shiyao (002788) at 9.33, up 5.19%, and Yingche Dong (002462) at 14.68, up 1.45% [1] - Conversely, Renmin Tongtai (600829) saw a significant drop of 9.98%, closing at 65.6 with a trading volume of 521,700 shares and a transaction value of 500 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 467 million from institutional investors, while retail investors saw a net inflow of 408 million [2] - The overall capital flow indicates that while institutional investors withdrew funds, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Notable net inflows from retail investors were observed in stocks like Yifeng Pharmacy (603939) with a retail net inflow of 412.67 million, while institutional investors had a net inflow of 287.47 million in Nanjing Pharmaceutical (600713) [3] - Conversely, stocks like Luyuan Pharmaceutical (002788) and Jia Shitang (002462) experienced net outflows from both institutional and retail investors [3]